BioMedReports.com is the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.
Thinly traded BioLineRx shares move on hepatitis C deal
The shares of thinly traded BioLineRx (NASDAQ:BLRX) soared as high as $5.86 following early morning news that the firm had signed a worldwide, exclusive license agreement with Genoscience and RFS Pharma to develop and commercialize BL-8030, an orally available treatment for Hepatitis C.
The stock was not able to hold on to the gains. Before the day was done, the stock sold off but still managed to close the day up 7.77% to at $4.44 +0.32 on Monday.
Register here to be notified of future Biomed articles.
